A Phase 2 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis D, Chronic, sponsored by Hoffmann-La Roche. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hepatitis D, Chronic with a site in Italy — 3 open to participants now, 6 under way, 2 of them phase 3. Hepatitis D, Chronic · Italy.
Among the 10 studies in Hepatitis D, Chronic with a site in Italy, this one is the only one that started in 2004, is one of 4 in phase 2, and was the 1st registered.
43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.
Browse Hepatitis D, Chronic studies →3 of the 10 studies in Hepatitis D, Chronic with a site in Italy are open now. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Italy, Austria, Czechia and 5 more countries
Ages 18+
Gilead Sciences · Sites in Italy, United States, Bulgaria and 6 more countries
Ages 18–69 · Healthy volunteers
Assembly Biosciences · Sites in Italy, France, Georgia and 8 more countries
Ages 18–70
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 6 Hepatitis D, Chronic studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 3
First in 2004; this study’s year is marked. 1 started in 2004.
This study's enrollment of 12 is below the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.
Median enrollment 95 across the 9 interventional studies, 515 across the 1 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 8 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Hepatitis D, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatitis D, Chronic with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07128550Phase 3Vir Biotechnology, Inc.A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | 2026-12 |
| NCT07454837Phase 3Mirum Pharmaceuticals, Inc.Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | 2027-08-31 |
| NCT07762027Assembly BiosciencesA Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Hepatitis D, Chronic with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
Drug: Peginterferon alfa-2a
Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
Also known as: Pegasys
Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
Also known as: Copegus
Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment
Normalized ALT was defined as ALT value above the upper limit of normal (ULN) at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). Negative HDV RNA was defined as HDV RNA not detected by polymerase chain reaction (PCR). The number of participants with ALT normalization and negative HDV RNA at Week 96 was reported.
Time frame: Week 96
Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment
Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with ALT normalization and negative HDV RNA at Week 48 was reported.
Time frame: Week 48
Number of Participants With ALT Normalization at 48 Weeks After End of Treatment
Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). The number of participants with ALT normalization at Week 96 was reported.
Time frame: Week 96
Number of Participants With ALT Normalization at End of Treatment
Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). The number of participants with ALT normalization at Week 48 was reported.
Time frame: Week 48
Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment
Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at 48 weeks after end of treatment (Week 96) was reported.
Time frame: Week 96
Number of Participants With Negative HDV RNA at End of Treatment
Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at the end of treatment (Week 48) was reported.
Time frame: Week 48
| Milestone | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 4 |
| Not completed | 0 | 2 |
| Withdrew: Psychiatric disorder | 0 | 1 |
| Withdrew: Refused therapy | 0 | 1 |
Normalized ALT was defined as ALT value above the upper limit of normal (ULN) at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). Negative HDV RNA was defined as HDV RNA not detected by polymerase chain reaction (PCR). The number of participants with ALT normalization and negative HDV RNA at Week 96 was reported.
| participants | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment | 0 | 1 |
Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with ALT normalization and negative HDV RNA at Week 48 was reported.
| participants | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment | 0 | 0 |
Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). The number of participants with ALT normalization at Week 96 was reported.
| participants | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Number of Participants With ALT Normalization at 48 Weeks After End of Treatment | 3 | 1 |
Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). The number of participants with ALT normalization at Week 48 was reported.
| participants | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Number of Participants With ALT Normalization at End of Treatment | 1 | 0 |
Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at 48 weeks after end of treatment (Week 96) was reported.
| participants | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment | 0 | 1 |
Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at the end of treatment (Week 48) was reported.
| participants | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| Number of Participants With Negative HDV RNA at End of Treatment | 1 | 2 |
Collected over Baseline through 24 weeks after end of treatment (up to 72 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Monotherapy With Peginterferon Alfa-2a | — | 0/6 (0%) | 6/6 (100%) |
| Group B: Combination With Peginterferon Alfa-2a + Ribavirin | — | 0/6 (0%) | 6/6 (100%) |
| Event | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin |
|---|---|---|
| AstheniaGeneral disorders | 5/6 | 3/6 |
| PyrexiaGeneral disorders | 5/6 | 3/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/6 | 2/6 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/6 | 2/6 |
| InsomniaPsychiatric disorders | 4/6 | 3/6 |
| AnxietyPsychiatric disorders | 0/6 | 4/6 |
| HeadacheNervous system disorders | 3/6 | 2/6 |
| DepressionPsychiatric disorders | 2/6 | 3/6 |
| IrritabilityPsychiatric disorders | 2/6 | 3/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/6 | 2/6 |
Intent-to-Treat (ITT) Population: All participants who received at least one dose of study medication.
| Age, Continuous(years) | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin | Total |
|---|---|---|---|
| Mean | 47.2 ± 9.2 | 49.2 ± 7.4 | 48.2 ± 8.0 |
| Sex: Female, Male(Participants) | Group A: Monotherapy With Peginterferon Alfa-2a | Group B: Combination With Peginterferon Alfa-2a + Ribavirin | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 5 | 6 | 11 |
The record gives a start of Sep 2004, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 7 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a